Correction
for
Apple and Wu, Clin Chem 47 (3) 377-379.
Clinical Chemistry 47: 981, 2001;
(Clinical Chemistry. 2001;47:981.)
© 2001 American Association for Clinical Chemistry, Inc.
Erratum
Fred S. Apple and
Alan H.B. Wu
In the Heart Health editorial "Myocardial Infarction
Redefined: Role of Cardiac Troponin Testing" by F. Apple and A.H.B.
Wu (Clin Chem 2001;47:377–9), the following addendum was
inadvertently omitted at printing.
Addendum: At a recent (January 26–27, 2001) "Acute
MI Guidelines Conference" sponsored by the Duke Clinical Research
Institute, a group of international cardiologists, including many of
those involved in crafting the newly proposed ESC/ACC guidelines,
convened to reemphasize the need to move forward with the
recommendations of the new consensus document (3). New and
recently published data were presented to the FDA and both the in vitro
diagnostic and pharmaceutical industries to explore ways to
(a) integrate cardiac troponin testing into acute coronary
syndrome clinical trials, and (b) push for the FDA and the
in vitro diagnostics industry to improve and more thoroughly document
the low end precision of all cardiac troponin assays presently in the
marketplace and those being assessed for 510K approval. The conference
members left with a clear understanding of the problems and were
supportive of the goals presented. This meeting no doubt will be
followed by increased interaction between all agencies (including a
major role for AACC) to move these efforts forward.
